Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Phase 3

Conditions: Non-Small Cell Lung Cancer(NSCLC)

Interventions: Drug: Paclitaxel Micelles for Injection
Drug: Paclitaxel Injection
Drug: Cisplatin

First Posted Date: 2016-01-29

Last Posted Date: 2021-03-17

Lead Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd.

Target Recruit Count: 454

Registration Number: NCT02667743

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳
Jiangsu Cancer Hospital, Nanjing, Zhejiang, China

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: Pembrolizumab
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2016-01-25

Last Posted Date: 2023-10-31

Lead Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Target Recruit Count: 28

Registration Number: NCT02662062

Locations: 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 4 locations

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Biological: AGS-003-LNG
Drug: Carboplatin
Drug: Abraxane
Drug: Alimta
Drug: Cisplatin
Drug: Taxol
Radiation: Radiation Therapy

First Posted Date: 2016-01-25

Last Posted Date: 2022-03-18

Lead Sponsor: GU Research Network, LLC

Registration Number: NCT02662634

Locations: 🇺🇸
Cancer Research Network of Nebraska / Oncology Associates, Omaha, Nebraska, United States

Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion

Phase 2

Conditions: Malignant Pleural Effusion

Interventions: Biological: tumor derived microparticles
Drug: cisplatin

First Posted Date: 2016-01-15

Last Posted Date: 2019-02-26

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 90

Registration Number: NCT02657460

Locations: 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2016-01-15

Last Posted Date: 2023-11-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 578

Registration Number: NCT02657434

Locations: 🇺🇸
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne, Indiana, United States
🇺🇸
Oncology Consultants PA, Houston, Texas, United States

and more 180 locations

D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)

Phase 1

Conditions: Lung Cancer
Non-small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Biological: D-CIK

First Posted Date: 2016-01-11

Last Posted Date: 2016-05-24

Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD

Target Recruit Count: 60

Registration Number: NCT02651441

Locations: 🇨🇳
Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

Phase 2

Conditions: Esophageal Cancer
Digestive System Neoplasms
Esophageal Neoplasms
Neoplasms

Interventions: Drug: Paclitaxel
Biological: DC-CIK
Drug: Cisplatin

First Posted Date: 2016-01-01

Last Posted Date: 2016-05-24

Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD

Target Recruit Count: 60

Registration Number: NCT02644863

Locations: 🇨🇳
Affiliated Tumor Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

Phase 3

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Docetaxel
Drug: Nedaplatin
Drug: Cisplatin

First Posted Date: 2015-12-31

Last Posted Date: 2015-12-31

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 488

Registration Number: NCT02643407

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer
Breast Cancer

Interventions: Drug: docetaxel
Drug: doxorubicin or epirubicin
Drug: cyclophosphamide
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2015-12-30

Last Posted Date: 2024-01-25

Lead Sponsor: Fudan University

Target Recruit Count: 503

Registration Number: NCT02641847

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Pembrolizumab
Procedure: Surgery
Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2015-12-29

Last Posted Date: 2024-08-29

Lead Sponsor: Trisha Wise-Draper

Target Recruit Count: 96

Registration Number: NCT02641093

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy